ReutersReuters

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz

Refinitiv1분 미만 읽기

Vanda Pharmaceuticals Inc VNDA:

  • VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®

이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오